ArticleOxford medical case reports2025
A case of corneal abscess following self-medication with topical dermatologic corticosteroids in a child.
Article in Oxford medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Topical dermatologic corticosteroids (TDC), while essential in treating skin conditions, can cause severe complications when misused, particularly in children. This case study reports a 7-year-old girl with a history of long-term self-medication with 0.05% betamethasone for dermatological lesions, resulting in iatrogenic Cushing's syndrome and a severe corneal abscess. The child presented with visual loss, corneal infiltrates, and hypopyon. Ocular and biochemical tests confirmed the diagnosis. The management included antifungal and antibacterial treatments, intrastromal voriconazole injection, and amniotic membrane grafting. TDC were gradually discontinued, and tacrolimus was used for skin symptoms. After 3 months, visual acuity improved to 3/10, with residual corneal opacity. This case emphasizes the dangers of prolonged TDC use without supervision and the need for early intervention in ocular complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.